Evidence map›Paper›PMID 41699362›Full record

ArticleDrug delivery and translational research2026

Statistical optimization of chitosan-based synthesis strategies to generate albumin nanoparticles.

Aitana Martín-Escaño, Claudia Barbuzano, Juan Manuel Rodríguez-Díaz, Edgar Pérez-Herrero

Abstract read
In one paragraph

Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Aitana Martín-EscañoGrupo de Investigación de Encapsulación y Evaluación Biológica Avanzada (ENCAPBIO-ULL Research Group), Departamento de Ingeniería Química y Tecnología Farmacéutica, Universidad de Laguna. Avda. Astrofisico Francisco Sánchez, S/N, 38206, San Cristóbal de La Laguna (Santa Cruz de Tenerife), Spain.
Claudia BarbuzanoGrupo de Investigación de Encapsulación y Evaluación Biológica Avanzada (ENCAPBIO-ULL Research Group), Departamento de Ingeniería Química y Tecnología Farmacéutica, Universidad de Laguna. Avda. Astrofisico Francisco Sánchez, S/N, 38206, San Cristóbal de La Laguna (Santa Cruz de Tenerife), Spain.
Juan Manuel Rodríguez-DíazDepartamento de Estadística, Instituto Universitario de Física Fundamental y Matemáticas, Universidad de Salamanca, 37008, Salamanca, Spain. juanmrod@usal.es.
Edgar Pérez-HerreroGrupo de Investigación de Encapsulación y Evaluación Biológica Avanzada (ENCAPBIO-ULL Research Group), Departamento de Ingeniería Química y Tecnología Farmacéutica, Universidad de Laguna. Avda. Astrofisico Francisco Sánchez, S/N, 38206, San Cristóbal de La Laguna (Santa Cruz de Tenerife), Spain. eperezhe@ull.edu.es.ORCID https://orcid.org/0000-0003-3483-2289

Funding

Agencia Estatal de Investigación PID2021-125211OB-I00Agencia Estatal de Investigación PID2022-142689OB-I00Fundación General Universidad de La Laguna NEUROnanoNASAL (Crowdfunding Campaign)Junta de Castilla y León SA217P23
6 · The paper itself

Abstract

Albumin-based nanoparticles (NPs) are typically synthesized by harsh conditions-based methods that limit their application in clinics and can seriously damage the entrapped drug and even their base material. Despite the potential of the use of chitosan (CS) as stabilizing agent by adapting the ionic gelation method or by adding CS as a coating to albumin NPs generated by desolvation, the influential factors of these methods have not yet been studied. In this article, these synthesis approaches have been optimized by a 2-step DoE-based methodology (a screening process with fractional designs plus a response surface methodology using central composite designs). The application of the ion gelation method to produce albumin-based NPs generates sizes from 66 to 1017 nm, PDI (polydispersity index) values of 0.3-0.6 and surface charges (ZP) from neutral to positive (> 20 mV). The fitted models of the responses depend on four factors (albumin and CS concentration, CS pH and CS:albumin mass ratio). On the other hand, the modification of the desolvation method using CS as a stabilizing coating generates 37-1305 nm NPs, with PDI between 0.4 and 0.7 and highly positive ZP (20-40 mV). In this case, the approximate models for the responses depend on four main effects (albumin and CS concentration, pH of CS and albumin:EtOH volume ratio). Furthermore, in this work the best combinations of factors and levels that allow minimizing PDI and obtaining the minimum and maximum expected values for mean size and ZP of NPs were determined for both synthesis methods. Focusing on the minimum possible PDI, the predicted values for the ion gelation- and desolvation-based methods are 0.363 and 0.341, respectively, which are achieved with values of [BSA] (mg/ml), [CS] (mg/ml), CS pH and CS:BSA or BSA:EtOH ratios (mL:mL) of {2.3,1.4,2.2,1:7.3} and {10,0.5,1.8,1:1}, respectively. These optimized conditions yield acceptable size and ZP values for the ion gelation-based (27.7 nm; 16.4 mV) and optimal values for the desolvation-based (146.2 nm; 29.5 mV).

Indexed as

ChitosanNanoparticlesSerum Albumin, BovineHydrogen-Ion ConcentrationParticle SizeChitosanSerum Albumin, BovineAlbuminChitosanDesign of experiments (DoE)NanoparticlesOptimization

Identifiers

PMID41699362
PMCPMC13538268

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.